Yakou Fumiyoshi, Suwanai Hirotsugu, Ishikawa Takuya, Itou Mariko, Shikuma Jumpei, Miwa Takashi, Sakai Hiroyuki, Kanekura Kohsuke, Narumi Satoshi, Suzuki Ryo, Odawara Masato
Tokyo Medical University, Department of Diabetes, Metabolism and Endocrinology, Tokyo 160-0023, Japan.
Tokyo Medical University, Department of Molecular Pathology, Tokyo 160-8402, Japan.
Int J Endocrinol. 2020 Aug 30;2020:9132372. doi: 10.1155/2020/9132372. eCollection 2020.
Congenital hypothyroidism (CH) is the most prevalent congenital endocrine disorder and causes mental retardation. A male Japanese patient with first cousin marriage parents was diagnosed as CH at 10 months. He was born before introduction of mass screening for CH. With continuous thyroid hormone replacement therapy, normal thyroid hormone status was maintained until adulthood. Genetic screening of next-generation sequencing was performed at the age of 52 years, and we identified a new homozygous thyroid peroxidase (TPO) gene mutation (GRCh38.p13, chromosome 2 at position 1493997, c.1964 G>T, p.Cys655Phe). TPO is an important enzyme to produce thyroid hormone. As demonstrated by a homology analysis of TPO proteins among different species, cysteine 655 residue is highly conserved, suggesting an important role in maintaining TPO function and structure. An study with three-dimensional structure of the novel mutation was performed and suggested that the mutation abolished disulfide bond between cysteines at positions 598 and 655. An functional analysis using HEK293 cells revealed that TPO activity of the mutant was significantly impaired compared with that of the wild type. Furthermore, study of immunohistochemistry showed that localization of TPO in cells did not differ between the wild type and the mutant. In conclusion, this single disulfide bond loss mutation of a new TPO homozygous mutation, p.Cys655Phe, reduced TPO activity and caused congenital hypothyroidism without affecting subcellular localization of TPO proteins.
先天性甲状腺功能减退症(CH)是最常见的先天性内分泌疾病,可导致智力发育迟缓。一名父母为近亲结婚的日本男性患者在10个月时被诊断为CH。他出生于CH大规模筛查引入之前。通过持续的甲状腺激素替代治疗,其甲状腺激素水平在成年前一直维持正常。在患者52岁时进行了下一代测序基因筛查,我们发现了一种新的纯合甲状腺过氧化物酶(TPO)基因突变(GRCh38.p13,位于2号染色体1493997位置,c.1964 G>T,p.Cys655Phe)。TPO是产生甲状腺激素的一种重要酶。通过对不同物种TPO蛋白的同源性分析表明,655位半胱氨酸残基高度保守,提示其在维持TPO功能和结构中起重要作用。对该新突变进行了三维结构研究,结果表明该突变消除了598位和655位半胱氨酸之间的二硫键。使用HEK293细胞进行的功能分析显示,与野生型相比,突变体的TPO活性显著受损。此外,免疫组织化学研究表明,野生型和突变体之间TPO在细胞中的定位没有差异。总之,这种新的TPO纯合突变p.Cys655Phe的单一二硫键缺失突变降低了TPO活性,导致先天性甲状腺功能减退症,且不影响TPO蛋白的亚细胞定位。